Sernova Corp., a regenerative medicine company, engages in the research and development of its proprietary Cell Pouch and associated technologies, including immune-protected therapeutic cells. The company focuses on developing a commercially-viable treatment for insulin-dependent human diabetes and other metabolic, blood, and neurological diseases with therapeutic cells placed into its implanted, prevascularized, and medical device protected from immune system attack. The company s Cell Pouch System is a device for the placement of therapeutic cells which becomes an organ-like structure with microvessels for the nutrition and protection of cells. It is also developing Sertolin, an immune protection technology that protects therapeutic cell types, such as insulin producing islets from immune system attack within the Cell Pouch. The company is headquartered in London, Canada.